Does Blue Cross Blue Shield of Michigan Cover Farxiga?

What Farxiga Is and Why Insurers Pay Attention

Farxiga (dapagliflozin) belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class. It works by blocking glucose reabsorption in the kidney's proximal tubule, which causes excess glucose to leave the body through urine. The FDA first approved it for type 2 diabetes in 2014, then expanded its indications to include heart failure with reduced ejection fraction in 2020 and chronic kidney disease in 2021 [1].

These expanded indications matter for insurance coverage decisions. BCBSM, like most large payers, evaluates drugs based on clinical evidence, cost-effectiveness relative to alternatives, and FDA labeling scope. SGLT2 inhibitors have accumulated substantial trial data. The DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin reduced the composite of cardiovascular death and hospitalization for heart failure by 17% compared to placebo in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors [2]. That kind of outcomes data influences formulary committees.

BCBSM is also Michigan's largest insurer, covering roughly 4.7 million members across commercial, Medicare Advantage, and Blue Care Network HMO products [3]. Because of that scale, its formulary decisions shape medication access for a significant share of the state's population. The insurer updates its formulary at least quarterly, so specific tier placements can shift. Always verify current status through your plan's online formulary tool or by calling the member services number on the back of your insurance card.

BCBSM Formulary Tier Placement for Farxiga

Farxiga sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) depending on which BCBSM product you carry. Tier placement directly controls your copay or coinsurance amount.

On most BCBSM commercial PPO plans, Farxiga appears at the preferred-brand level, which typically means a fixed copay between $30 and $60 for a 30-day supply [4]. Blue Care Network HMO plans may place it one tier higher, at the non-preferred brand level, which can push the copay to $60 to $90. Medicare Advantage plans under BCBSM (branded as Medicare Plus Blue) use a five-tier structure, and Farxiga generally falls on Tier 3 (preferred brand) with coinsurance of 25% to 33% after any applicable deductible [5].

A critical point: formulary tier alone does not guarantee access. BCBSM applies utilization management criteria on top of tier placement. Even if Farxiga appears on your formulary, your pharmacy may reject the claim until prior authorization is completed.

The American Diabetes Association's 2024 Standards of Care recommends SGLT2 inhibitors as second-line therapy after metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [6]. This guideline alignment is precisely what BCBSM's medical policy references when adjudicating prior authorization requests for Farxiga.

Prior Authorization Requirements

BCBSM requires prior authorization for Farxiga on the majority of its plan types. Your prescribing physician's office submits clinical documentation to BCBSM before the pharmacy can fill the prescription. Expect the process to take 3 to 5 business days for standard requests.

The typical criteria BCBSM evaluates include: a confirmed diagnosis of type 2 diabetes, heart failure (NYHA class II-IV), or chronic kidney disease with eGFR between 25 and 75 mL/min/1.73 m²; documented trial and failure of, intolerance to, or contraindication for metformin (for diabetes indication); current HbA1c level (usually required to be 7.0% or above for diabetes); and confirmation that the prescriber has considered formulary-preferred alternatives [7].

For heart failure and CKD indications specifically, the prior authorization pathway may be more straightforward. The DAPA-HF trial (N=4,744) showed a 26% reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin versus placebo (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001) [8]. The DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes (HR 0.61; 95% CI, 0.51 to 0.72; P<0.001) [9]. These strong outcomes data mean that BCBSM medical reviewers are less likely to require step therapy for cardiac and renal indications.

Dr. Brendan Everett, a cardiologist at Brigham and Women's Hospital, has noted: "The evidence base for SGLT2 inhibitors in heart failure is now so consistent across trials that restricting access through burdensome prior authorization is difficult to justify clinically" [10].

If your prior authorization is denied, you have the right to appeal. BCBSM allows standard appeals to be filed within 60 days of the denial notice, with a decision rendered within 30 calendar days [4].

Step Therapy and Alternatives BCBSM May Require

Step therapy means your insurer requires you to try a less expensive medication first before approving the one your doctor prescribed. BCBSM commonly applies step therapy to Farxiga when it is prescribed for type 2 diabetes.

The usual first step is metformin, which remains the most widely prescribed first-line oral diabetes drug in the United States and costs as little as $4 per month at many pharmacies [11]. BCBSM's clinical policy aligns with ADA guidelines that recommend metformin as initial pharmacologic therapy for most adults with type 2 diabetes [6]. If your physician documents that you have already tried metformin and either did not reach your HbA1c target or experienced side effects (gastrointestinal intolerance is common, affecting up to 25% of patients), Farxiga can typically be approved without additional step requirements [12].

BCBSM may also suggest therapeutic alternatives within the SGLT2 class. Jardiance (empagliflozin) sometimes occupies a more favorable formulary position on certain BCBSM sub-plans. If Jardiance is preferred on your specific formulary, your physician can either prescribe the preferred agent or submit a medical exception explaining why Farxiga is specifically needed. Reasons might include prior adverse reaction to empagliflozin, the CKD indication (where dapagliflozin has the DAPA-CKD trial data), or specific dose considerations.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated in 2023: "Step therapy requirements should not delay access to medications with proven cardiovascular and renal benefits when patients meet guideline-based criteria for their use" [13].

What You Will Pay Out of Pocket

Your actual cost depends on your plan design, tier placement, deductible status, and whether you use available savings programs. Here is a breakdown of typical scenarios for BCBSM members.

For commercial PPO members with Farxiga at Tier 2, copays typically run $30 to $50 per month after prior authorization approval. Tier 3 placement pushes that range to $60 to $90. If your plan uses coinsurance instead of flat copays, expect 25% to 40% of the negotiated drug price, which could mean $75 to $150 before reaching the out-of-pocket maximum [4].

AstraZeneca offers a manufacturer copay savings card for commercially insured patients that can reduce the out-of-pocket cost to as low as $0 per month, with a maximum annual benefit that has historically been set around $1,800 [14]. This card does not apply to government-funded insurance (Medicare, Medicaid, Tricare). Eligibility requires commercial insurance and a valid prescription.

For Medicare Plus Blue members, the cost structure follows the Part D benefit design. During the initial coverage phase, coinsurance of 25% to 33% applies. Once total drug spending hits the catastrophic coverage threshold ($8,000 in true out-of-pocket costs for 2025), the patient pays $0 or a small copay for each prescription for the remainder of the year [5]. AstraZeneca also maintains a patient assistance program for Medicare beneficiaries who meet income criteria.

Retail price without any insurance runs approximately $550 to $620 for a 30-day supply of Farxiga 10 mg [15]. This number underscores why securing insurance coverage matters.

How to Get Farxiga Approved on Your BCBSM Plan

Getting coverage approved involves a sequence of concrete steps. The process is not automatic, but it is manageable when you know what BCBSM expects.

Start by asking your prescriber's office to check the BCBSM online portal for your specific formulary. BCBSM maintains separate formularies for its commercial PPO plans, Blue Care Network HMO plans, and Medicare Advantage products. Confirm which one applies to you.

Next, ensure your medical records document the clinical basis for Farxiga. For diabetes, this means a recent HbA1c value, a record of prior metformin use (or documented contraindication), and a note about any cardiovascular or renal comorbidities that would make SGLT2 inhibitor therapy guideline-recommended [6]. For heart failure, documentation of NYHA functional class and ejection fraction is standard. For CKD, a recent eGFR and urine albumin-to-creatinine ratio should be in the chart.

Your prescriber submits the prior authorization request to BCBSM, typically through the CoverMyMeds electronic platform or by fax. BCBSM aims to process standard requests within 72 hours, though complex cases may take up to 5 business days [4].

If the request is denied, read the denial letter carefully. It will specify the exact reason (missing documentation, step therapy not completed, alternative preferred). Your prescriber can then either supply the missing information and resubmit, or file a formal appeal with a letter of medical necessity citing relevant trial data and guideline recommendations.

One practical tip: if your prescriber cites the DAPA-CKD or DAPA-HF trial results in the prior authorization submission, approval rates tend to be higher for the CKD and heart failure indications than for diabetes alone. Payers respond to hard endpoints like reduced mortality and hospitalization.

Farxiga Coverage for Heart Failure and CKD Indications

BCBSM coverage policies increasingly distinguish between Farxiga prescribed for diabetes versus its cardiac and renal indications. This distinction matters because the evidence base differs, and so do the utilization management criteria.

For heart failure, the FDA approved dapagliflozin across the full spectrum of ejection fractions (HFrEF and HFpEF) based on the DAPA-HF and DELIVER trials. The DELIVER trial (N=6,263) showed that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 18% in patients with heart failure and mildly reduced or preserved ejection fraction (EF >40%), regardless of diabetes status (HR 0.82; 95% CI, 0.73 to 0.92; P<0.001) [16]. BCBSM recognizes this indication and may waive the metformin step therapy requirement when Farxiga is prescribed specifically for heart failure.

For CKD, the DAPA-CKD trial enrolled patients with eGFR 25 to 75 mL/min/1.73 m² and a urine albumin-to-creatinine ratio of 200 to 5,000 mg/g, with or without type 2 diabetes [9]. The trial was stopped early for efficacy. BCBSM's medical policy for dapagliflozin in CKD typically requires documentation of eGFR within the approved range and evidence of albuminuria, along with use of a maximally tolerated dose of an ACE inhibitor or ARB.

If your physician is prescribing Farxiga for heart failure or CKD rather than diabetes, make sure the prior authorization form reflects the correct indication. Submitting under the wrong indication code can trigger unnecessary step therapy requirements or outright denial.

What Happens If Coverage Is Denied

A denial is not the final word. BCBSM provides a structured appeals process, and overturning an initial denial is more common than most patients realize.

The first step after denial is a peer-to-peer review, where your prescribing physician speaks directly with a BCBSM medical director. This conversation allows your doctor to explain why Farxiga is medically necessary for your specific clinical situation. Many denials are reversed at this stage, particularly when the prescriber presents trial-level evidence [4].

If the peer-to-peer does not resolve the issue, you can file a formal internal appeal. BCBSM must respond to standard internal appeals within 30 calendar days. The appeal should include a letter of medical necessity, relevant lab results, documentation of prior medication trials, and citations to clinical guidelines or trial data supporting Farxiga use.

Beyond internal appeals, Michigan insurance regulations provide an external review option through the Michigan Department of Insurance and Financial Services (DIFS). External review involves an independent physician reviewer who is not employed by BCBSM. Under Michigan law, the external reviewer's decision is binding on the insurer [17].

Keep records of every communication, including denial letters, appeal submissions, and dates of phone calls. Document the names of BCBSM representatives you speak with.

Comparing Farxiga Coverage Across Michigan Insurers

BCBSM is not the only insurer in Michigan, and coverage policies vary. If you are choosing a plan during open enrollment or considering a switch, comparing SGLT2 inhibitor coverage across carriers is worth the effort.

Priority Health, Michigan's second-largest insurer, also covers Farxiga but may place it at a different tier depending on the plan year [18]. HAP (Health Alliance Plan) covers SGLT2 inhibitors on most commercial plans but has historically preferred Jardiance over Farxiga on its formulary. Medicaid coverage in Michigan (through Healthy Michigan Plan managed care organizations) includes Farxiga but requires prior authorization and typically mandates metformin step therapy [19].

For Medicare beneficiaries, the Medicare Plan Finder tool at medicare.gov allows you to compare Part D formularies by specific drug. Enter your zip code and the drug name to see which Medicare Advantage or Part D plans cover Farxiga at the most favorable tier in your area.

The ADA's 2024 Standards of Care explicitly states: "Cost and insurance coverage should be considered when selecting glucose-lowering medications, particularly for patients with cardiovascular or renal comorbidities who would benefit from SGLT2 inhibitors or GLP-1 receptor agonists" [6]. If your current plan makes Farxiga prohibitively expensive, discuss therapeutic alternatives and plan switching options with both your physician and a benefits counselor.